Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1954 1
1955 1
1956 2
1958 1
1959 2
1961 1
1963 5
1964 4
1965 3
1966 3
1967 6
1968 2
1969 5
1970 2
1971 1
1973 2
1974 2
1975 2
1976 1
1977 1
1982 8
1983 9
1984 8
1985 10
1986 13
1987 11
1988 5
1989 14
1990 17
1991 13
1992 10
1993 11
1994 17
1995 10
1996 17
1997 18
1998 11
1999 21
2000 31
2001 27
2002 25
2003 39
2004 26
2005 36
2006 39
2007 43
2008 47
2009 57
2010 45
2011 43
2012 47
2013 58
2014 53
2015 47
2016 67
2017 61
2018 64
2019 71
2020 84
2021 80
2022 99
2023 64

Text availability

Article attribute

Article type

Publication date

Search Results

1,375 results

Results by year

Filters applied: . Clear all
Page 1
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.
Abramson JS, Palomba ML, Gordon LI, Lunning MA, Wang M, Arnason J, Mehta A, Purev E, Maloney DG, Andreadis C, Sehgal A, Solomon SR, Ghosh N, Albertson TM, Garcia J, Kostic A, Mallaney M, Ogasawara K, Newhall K, Kim Y, Li D, Siddiqi T. Abramson JS, et al. Among authors: ogasawara k. Lancet. 2020 Sep 19;396(10254):839-852. doi: 10.1016/S0140-6736(20)31366-0. Epub 2020 Sep 1. Lancet. 2020. PMID: 32888407 Clinical Trial.
Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial.
Kamdar M, Solomon SR, Arnason J, Johnston PB, Glass B, Bachanova V, Ibrahimi S, Mielke S, Mutsaers P, Hernandez-Ilizaliturri F, Izutsu K, Morschhauser F, Lunning M, Maloney DG, Crotta A, Montheard S, Previtali A, Stepan L, Ogasawara K, Mack T, Abramson JS; TRANSFORM Investigators. Kamdar M, et al. Among authors: ogasawara k. Lancet. 2022 Jun 18;399(10343):2294-2308. doi: 10.1016/S0140-6736(22)00662-6. Lancet. 2022. PMID: 35717989 Clinical Trial.
A Pragmatic, Randomized Clinical Trial of Gestational Diabetes Screening.
Hillier TA, Pedula KL, Ogasawara KK, Vesco KK, Oshiro CES, Lubarsky SL, Van Marter J. Hillier TA, et al. Among authors: ogasawara kk. N Engl J Med. 2021 Mar 11;384(10):895-904. doi: 10.1056/NEJMoa2026028. N Engl J Med. 2021. PMID: 33704936 Free PMC article. Clinical Trial.
Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study.
Sehgal A, Hoda D, Riedell PA, Ghosh N, Hamadani M, Hildebrandt GC, Godwin JE, Reagan PM, Wagner-Johnston N, Essell J, Nath R, Solomon SR, Champion R, Licitra E, Fanning S, Gupta N, Dubowy R, D'Andrea A, Wang L, Ogasawara K, Thorpe J, Gordon LI. Sehgal A, et al. Among authors: ogasawara k. Lancet Oncol. 2022 Aug;23(8):1066-1077. doi: 10.1016/S1470-2045(22)00339-4. Epub 2022 Jul 12. Lancet Oncol. 2022. PMID: 35839786 Clinical Trial.
Japan Stroke Society Guideline 2021 for the Treatment of Stroke.
Miyamoto S, Ogasawara K, Kuroda S, Itabashi R, Toyoda K, Itoh Y, Iguchi Y, Shiokawa Y, Takagi Y, Ohtsuki T, Kinouchi H, Okada Y, Takahashi JC, Nakase H, Kakuda W; Committee for Stroke Guideline 2021, the Japan Stroke Society. Miyamoto S, et al. Among authors: ogasawara k. Int J Stroke. 2022 Oct;17(9):1039-1049. doi: 10.1177/17474930221090347. Epub 2022 Apr 20. Int J Stroke. 2022. PMID: 35443847 Free PMC article.
2021 Japanese Guidelines for the Management of Moyamoya Disease: Guidelines from the Research Committee on Moyamoya Disease and Japan Stroke Society.
Fujimura M, Tominaga T, Kuroda S, Takahashi JC, Endo H, Ogasawara K, Miyamoto S; Research Committee on Moyamoya Disease (Spontaneous Occlusion of Circle of Willis) of the Ministry of Health, Labor Welfare, Japan; Guideline Committee 2021 of the Japan Stroke Society. Fujimura M, et al. Among authors: ogasawara k. Neurol Med Chir (Tokyo). 2022 Apr 15;62(4):165-170. doi: 10.2176/jns-nmc.2021-0382. Epub 2022 Feb 22. Neurol Med Chir (Tokyo). 2022. PMID: 35197402 Free PMC article. No abstract available.
Human ABO gene transcriptional regulation.
Kominato Y, Sano R, Takahashi Y, Hayakawa A, Ogasawara K. Kominato Y, et al. Among authors: ogasawara k. Transfusion. 2020 Apr;60(4):860-869. doi: 10.1111/trf.15760. Epub 2020 Mar 26. Transfusion. 2020. PMID: 32216153 Free PMC article. Review. No abstract available.
[Preface].
Ogasawara K. Ogasawara K. Nihon Hoshasen Gijutsu Gakkai Zasshi. 2018;74(10):1235. doi: 10.6009/jjrt.2018_JSRT_74.10.1235. Nihon Hoshasen Gijutsu Gakkai Zasshi. 2018. PMID: 30344223 Free article. Japanese. No abstract available.
The KANNO blood group system.
Ohto H, Uchikawa M, Ito S, Wada I, Nollet KE, Omae Y, Ogasawara K, Tokunaga K. Ohto H, et al. Among authors: ogasawara k. Immunohematology. 2022 Dec 28;38(4):119-122. doi: 10.21307/immunohematology-2022-053. Print 2022 Dec 1. Immunohematology. 2022. PMID: 36789458
[JSRT Member "Dr. Takeshi Togashi"].
Ogasawara K. Ogasawara K. Nihon Hoshasen Gijutsu Gakkai Zasshi. 2022;78(8):867-870. doi: 10.6009/jjrt.2022-2063. Nihon Hoshasen Gijutsu Gakkai Zasshi. 2022. PMID: 35989255 Free article. Japanese. No abstract available.
1,375 results